Clinical Trial Search

Primary: Rate of Moderate or Severe COPD Exacerbations Per Patient Per Year — 0.805; 0.927 exacerbations per patient per year — p=0.0529

Primary: Proportion of Subjects With Non-Surgical Resolution of Vitreomacular Adhesion (VMA) — 52.2; 1.8 percentage of subjects

Primary: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Score at Week 24 in Intent-to-treat (ITT) Population — 21.2; 5.4 units on a…

Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Hour 0 to Infinity (AUC0-∞) — 23.3; 24.9 µM*hr

Primary: Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue During Phase A — 59.5; 53.8; 54.5; 60.0 Percentage of…

Primary: Efficacy, Measured by a Change in HbA1c Levels — 5.09; 5.2; 5.5; 5.8 percent of glycosylated hemoglobin

Primary: Hemoglobin Levels at Monthly Intervals — 11.15; 11.31; 11.33; 11.28 g/dL

Primary: Percentage of Patients With Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine. — 27 percentage of patients

Primary: Rate of Rise of Serum PSA — 0.0825 Nanograms Per Milliliter

Primary: Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183 — 97.6; 96.6 Percentage of subjects

Primary: Implant Location/Assessment of Alignment — 1.70; 1.91 degrees — p=<0.001

Primary: Sustained Virological Response 12 Weeks Post Treatment (SVR12) — 10.3; 65.4; 61.4; 33.8 percentage of participants — p=<0.0001

Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 27.6; 58.9; 36.8; 17.1 percentage of participants — p=<0.001

Primary: Percent Change in Inflammatory Lesions From Baseline to Week 16 — -83; -73.7 percentage of change

Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 26.0; 41.8; 29.8; 21.4 percentage of participants — p==0.003